Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02291913
What this trial is testing

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
SCRI Development Innovations, LLC 48
Testing effectiveness (Phase 2)Ended earlyNCT04675827
What this trial is testing

De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

Who this might be right for
HER2-positive Breast CancerER-Negative Breast CancerPR-Negative Breast Cancer+1 more
Jules Bordet Institute 139
Testing effectiveness (Phase 2)Looking for participantsNCT04683679
What this trial is testing

Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerBreast Cancer+1 more
Memorial Sloan Kettering Cancer Center 34
Large-scale testing (Phase 3)Study completedNCT01740427
What this trial is testing

Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Who this might be right for
Breast Neoplasms
Pfizer 666
Testing effectiveness (Phase 2)Looking for participantsNCT07796880
What this trial is testing

Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHER2 Low Breast CarcinomaEarly-Stage Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 80
Testing effectiveness (Phase 2)Study completedNCT00546156
What this trial is testing

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Who this might be right for
Breast Cancer
Ian E. Krop, MD, PhD 104
Testing effectiveness (Phase 2)Looking for participantsNCT06525766
What this trial is testing

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen-receptor-positive Breast CancerMetastatic HER2-Negative Breast Carcinoma+1 more
Mayo Clinic 35
Testing effectiveness (Phase 2)Looking for participantsNCT05398861
What this trial is testing

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Who this might be right for
HER-2 Negative Breast Cancer
Henan Cancer Hospital 79
Not applicableNot Yet RecruitingNCT07387861
What this trial is testing

PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study

Who this might be right for
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Assiut University 70
Testing effectiveness (Phase 2)UnknownNCT05927779
What this trial is testing

Study of TFX06 in Women With Advanced Breast Cancer.

Who this might be right for
ER+, HER2- Advanced Breast CancerMetastatic Breast Cancer
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. 74
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Large-scale testing (Phase 3)Not Yet RecruitingNCT07406542
What this trial is testing

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 400
Testing effectiveness (Phase 2)Active Not RecruitingNCT03789110
What this trial is testing

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 30
Testing effectiveness (Phase 2)Looking for participantsNCT06827613
What this trial is testing

Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerHR+, HER2-, Advanced Breast Cancer
Marengo Therapeutics, Inc. 50
Early research (Phase 1)WithdrawnNCT06229392
What this trial is testing

Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

Who this might be right for
Breast CancerBreast Cancer Triple Negative
Rush University Medical Center
Large-scale testing (Phase 3)WithdrawnNCT03081234
What this trial is testing

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT01036087
What this trial is testing

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 47
Testing effectiveness (Phase 2)Active Not RecruitingNCT05607004
What this trial is testing

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Who this might be right for
Breast NeoplasmsInvasive Breast CancerEstrogen-receptor-positive Breast Cancer+1 more
Atossa Therapeutics, Inc. 87
Testing effectiveness (Phase 2)Study completedNCT02789332
What this trial is testing

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more
GBG Forschungs GmbH 107
Early research (Phase 1)Active Not RecruitingNCT05508906
What this trial is testing

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 190
Next Page